Primary |
Premedication |
38.5% |
Prophylaxis |
13.6% |
Prophylaxis Of Nausea And Vomiting |
8.9% |
Breast Cancer Recurrent |
7.7% |
Metastases To Bone |
7.7% |
Breast Cancer |
4.1% |
Drug Use For Unknown Indication |
3.6% |
Pancreatic Neoplasm |
3.6% |
Breast Cancer Metastatic |
3.0% |
Rectal Cancer Metastatic |
1.8% |
Antiemetic Supportive Care |
1.2% |
Glioblastoma |
1.2% |
Nausea |
1.2% |
Vomiting |
1.2% |
Analgesic Therapy |
0.6% |
Anticachectic Therapy |
0.6% |
Gastric Cancer |
0.6% |
Mantle Cell Lymphoma |
0.6% |
Pain |
0.6% |
|
Pulmonary Artery Thrombosis |
17.2% |
Palmar-plantar Erythrodysaesthesia Syndrome |
10.3% |
Death |
6.9% |
Myalgia |
6.9% |
Tumour Lysis Syndrome |
6.9% |
Alopecia |
3.4% |
Decreased Appetite |
3.4% |
Dyskinesia |
3.4% |
Fatigue |
3.4% |
Febrile Neutropenia |
3.4% |
Gastrointestinal Perforation |
3.4% |
Haemolytic Anaemia |
3.4% |
Hepatitis Cholestatic |
3.4% |
Hyperventilation |
3.4% |
Ileus |
3.4% |
Injection Site Extravasation |
3.4% |
Lung Neoplasm Malignant |
3.4% |
Lymphopenia |
3.4% |
Malaise |
3.4% |
Neutropenia |
3.4% |
|
Secondary |
Premedication |
26.7% |
Breast Cancer |
12.1% |
Prophylaxis Of Nausea And Vomiting |
11.1% |
Prophylaxis |
7.9% |
Breast Cancer Metastatic |
7.0% |
Breast Cancer Recurrent |
6.5% |
Rectal Cancer Metastatic |
5.8% |
Metastases To Bone |
5.3% |
Acute Lymphocytic Leukaemia |
3.2% |
Therapeutic Embolisation |
2.8% |
Drug Use For Unknown Indication |
2.1% |
Product Used For Unknown Indication |
1.9% |
Evidence Based Treatment |
1.4% |
Gastric Cancer |
1.4% |
Rectal Cancer |
1.2% |
B-cell Lymphoma |
0.9% |
Antifungal Prophylaxis |
0.7% |
Colon Cancer Metastatic |
0.7% |
Dyspnoea |
0.7% |
Feeling Hot |
0.7% |
|
Inappropriate Antidiuretic Hormone Secretion |
12.2% |
Palmar-plantar Erythrodysaesthesia Syndrome |
10.2% |
Pulmonary Artery Thrombosis |
10.2% |
Renal Impairment |
8.2% |
Alopecia |
6.1% |
Injection Site Extravasation |
6.1% |
Stomatitis |
6.1% |
Swollen Tongue |
6.1% |
Anaphylactic Shock |
4.1% |
Fatigue |
4.1% |
Malaise |
4.1% |
Metastases To Bone |
4.1% |
Rash |
4.1% |
Constipation |
2.0% |
Death |
2.0% |
Decreased Appetite |
2.0% |
Dehydration |
2.0% |
General Physical Health Deterioration |
2.0% |
Hepatitis Cholestatic |
2.0% |
Hyponatraemia |
2.0% |
|
Concomitant |
Product Used For Unknown Indication |
38.7% |
Prophylaxis |
13.3% |
Infection Prophylaxis |
6.6% |
Premedication |
5.5% |
Bone Marrow Conditioning Regimen |
5.3% |
Prophylaxis Against Graft Versus Host Disease |
5.0% |
Drug Use For Unknown Indication |
3.9% |
Prophylaxis Of Nausea And Vomiting |
3.9% |
Antifungal Prophylaxis |
2.4% |
Constipation |
2.0% |
Colon Cancer |
1.7% |
Breast Cancer |
1.7% |
Antiviral Prophylaxis |
1.5% |
B-cell Lymphoma |
1.5% |
Acute Myeloid Leukaemia |
1.3% |
Extranodal Marginal Zone B-cell Lymphoma (Malt Type) |
1.3% |
Antibiotic Prophylaxis |
1.1% |
Colorectal Cancer |
1.1% |
Prophylaxis Against Gastrointestinal Ulcer |
1.1% |
Hypertension |
1.0% |
|
White Blood Cell Count Decreased |
19.3% |
Tumour Lysis Syndrome |
13.8% |
Pyrexia |
9.3% |
Vomiting |
7.8% |
Neutropenia |
5.2% |
Platelet Count Decreased |
4.8% |
Cytomegalovirus Infection |
3.3% |
Hiccups |
3.3% |
Wound Complication |
3.3% |
Cerebral Infarction |
3.0% |
Decreased Appetite |
3.0% |
Febrile Neutropenia |
3.0% |
Pruritus |
3.0% |
Stomatitis |
3.0% |
Tooth Loss |
3.0% |
Infection |
2.6% |
Pneumonia |
2.6% |
Device Related Infection |
2.2% |
Hepatic Function Abnormal |
2.2% |
Lymphocyte Count Decreased |
2.2% |
|